Do you have recurrent pericarditis?
Announcing a Clinical Trial for this Often Painful Inflammatory Disease
People age 12 and over who have been diagnosed with recurrent pericarditis may be eligible to participate in a clinical study.
The RHAPSODY study is testing the efficacy and safety of a potential new medication, rilonacept.
Talk to your doctor about whether you may be eligible.
About the RHAPSODY Study
This RHAPSODY Study is being done to learn if a medicine called rilonacept is an effective and safe treatment for recurrent pericarditis.
Rilonacept (KPL-914) is a recombinant fusion protein that blocks IL-1 alpha and IL-1 beta signaling that is responsible for many inflammatory processes and may be a factor in pericarditis. Kiniksa is evaluating the efficacy and safety of rilonacept in participants with recurrent pericarditis to potentially address the unmet need in the treatment of this disease.
Are You Eligible for the Study?
The RHAPSODY study will involve up to 75 people ages 12 years and up, in multiple countries. In order to qualify, you must have a confirmed diagnosis of recurrent pericarditis and must currently be experiencing at least your third episode. There are other requirements for the study. Talk to your doctor about whether you might be a candidate.